Chignolo D’Isola, Bergamo, Italy – November 5, 2020 – Flamma SpA (“Flamma”), a
preeminent Contract Development and Manufacturing Organization (CDMO) that develops,
manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs)
for the pharmaceutical industry, is proud to announce that it has entered into an agreement
with Gilead earlier this year to be part of the network of manufacturers contributing to the
Veklury® (remdesivir) supply chain.
Flamma will continue to use its sites in Italy and China to support the need for necessary
compounds in an effort to help COVID-19 patients in need.
“Covid-19 hit very close to home as Flamma is located in the Bergamo, one of the most
affected areas in Italy. Our facility in Dalian, China remained in full operation after the
extended Chinese New Year after adding proper precautions to protect the safety and health
of its employees,” noted Gian Paolo Negrisoli, CEO. “Our Italian team members utilized the
protocols learned from our Chinese team and instituted them in Italy. This allowed our teams
there to continue to support our customers with little to no interruption to the supply chain”.
The Flamma team has strived to provide continuous manufacturing support for remdesivir,
maintaining timelines for current and upcoming projects due to the global and local needs.
“This pandemic brought forth many challenges but Flamma responded to all of them with
dedication and a team spirit by working tirelessly to be a part of the pharmaceutical supply
chain to help those in need” notes Kenneth Drew, Ph.D., VP Flamma, USA.
During the Covid-19 crisis, Flamma teams in Italy and China have continued production of
important molecules that are critical to help fight the virus. The Italian team hung a sign
reading #MOLAMIA which means ‘Don’t Give Up’. Flamma doesn’t give up. This is another
example of the commitment, made to not only customers but employees, to be a first-class
organization. Flamma is very proud of the opportunity to support Gilead and remdesivir in the
fight against Covid-19, and will continue to do all it can to be active partner in the development
of breakthrough treatments.
About Veklury® (remdesivir):
Veklury (remdesivir) is an investigational nucleotide analog invented by Gilead, building on
more than a decade of the company’s antiviral research. Multiple ongoing international Phase
3 clinical trials are evaluating the safety and efficacy of Veklury for the treatment of COVID-
19. Based on available data from these studies, Veklury has been approved or authorized
for temporary use as a COVID-19 treatment in approximately 50 countries worldwide.
Additional ongoing international clinical trials continue to further evaluate the safety and
efficacy of Veklury in different patient populations and formulations, and in combination with
FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in
Northern Italy) established in 1950.
FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and
advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in
high value chiral materials specifically amino acid related materials. Flamma also
manufactures specialty compounds and advanced intermediates for the nutraceutical and
cosmetic industries and has several generic products.
FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA.
Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA.
Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP
production plant. Flamma provides security when working in China with our 100% owned,
self-managed facilities that deliver results without worry. Flamma reliably supplies materials
directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver
the customer’s compound on-time and with the desired specifications. Flamma offers costeffective
services to customers looking for a trusted partner within China.
The Malvern, PA site located outside Philadelphia provides Flamma with the ability to service
customers looking to keep materials within the USA for pre-clinical/early stage clinical
development as well as small scale commercial manufacturing.
Being a fully integrated company allows Flamma to move your compounds quickly along their
journey taking into consideration all aspects necessary for the success of your project.
Flamma can be of assistance for early stage pre-clinical development of small molecules as
well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and
over 600 employees, see why Flamma should be your next contract manufacturer.
FLAMMA – THE THINKING CDMO (TM)
For more information, please visit www.flammagroup.com
Kenneth Drew, Ph.D., VP Flamma USA